The secondary analysis of Comparison of Age-Related Macular Degeneration Treatment Trial (CATT)1 data performed by Ramakrishnan et al2 in this issue of JAMA Ophthalmology investigates the association between visit adherence and visual acuity in individuals with neovascular age-related macular degeneration (AMD). Anti–vascular endothelial growth factor injections have introduced a paradigm shift in how ophthalmologists treat patients with neovascular AMD. However, these treatments come at considerable costs, including the treatment burden on patients. Frequent office visits place stress on a patient population that includes elderly individuals and individuals with visual impairments, leading to missed visits and loss to follow-up. The authors set out to better understand the association between office-visit adherence and visual outcomes in patients receiving anti–vascular endothelial growth factor therapy for neovascular AMD.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Patel S, Sternberg P. Association Between Visit Adherence and Visual Acuity in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. Published online February 06, 2020. doi:10.1001/jamaophthalmol.2019.4644
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: